Efficient Suppression of Minority Drug‐Resistant HIV Type 1 (HIV‐1) Variants Present at Primary HIV‐1 Infection by Ritonavir‐Boosted Protease Inhibitor–Containing Antiretroviral Therapy | Zendy

Karin J. Metzner | Zendy; Pia Rauch | Zendy; Viktor von Wyl | Zendy; Christine Leemann | Zendy; Christina Grube | Zendy; Herbert Kuster | Zendy; Jürg Böni | Zendy; Rainer Weber | Zendy; Huldrych F. Günthard | Zendy

Open Access

Efficient Suppression of Minority Drug‐Resistant HIV Type 1 (HIV‐1) Variants Present at Primary HIV‐1 Infection by Ritonavir‐Boosted Protease Inhibitor–Containing Antiretroviral Therapy

Author(s) -

Karin J. Metzner,

Pia Rauch,

Viktor von Wyl,

Christine Leemann,

Christina Grube,

Herbert Kuster,

Jürg Böni,

Rainer Weber,

Huldrych F. Günthard

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/651136

Subject(s) - ritonavir , protease inhibitor (pharmacology) , virology , drug resistance , reverse transcriptase inhibitor , reverse transcriptase , nucleoside reverse transcriptase inhibitor , regimen , hiv drug resistance , protease , medicine , lentivirus , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , immunology , viral disease , biology , genetics , polymerase chain reaction , enzyme , gene , biochemistry

Selection of preexisting minority variants of drug-resistant human immunodeficiency virus type 1 (HIV-1) can lead to virological failure in patients who receive antiretroviral therapy (ART) with low genetic resistance barriers. We studied treatment response and dynamics of minority variants during the first weeks of ART containing a ritonavir-boosted protease inhibitor (PI) and 2 nucleoside reverse-transcriptase inhibitors (NRTIs), which is a regimen with a high genetic resistance barrier.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research